SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today highlighted the presentation of data from its first-in-human Phase 1 study of MAR002 at the 2026 Annual Meeting of the Endocrine Society (ENDO). MAR002 is a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR). Da